This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

III. Clinical Implications of UGDP Results

Martin G. Goldner, MD; Genell L. Knatterud, PhD; Thaddeus E. Prout, MD

JAMA. 1971;218(9):1400-1410.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

"Field (clinical) trials are indispensable. They will continue to be an ordeal. They lack glamour, they strain our resources and our patience, and they protract the moment of truth to excruciating limits. Still, they are among the most challenging tests of our skills.... If, in major medical dilemmas the alternative is to pay the cost of perpetual uncertainty, have we really any choice?"¹

The clinical trial of the effect of hypoglycemic agents on the vascular complications of diabetes mellitus conducted by the University Group Program (UGDP) for the past ten years bears witness to the truthfulness of the above quotation.

The hypothesis that control of the blood glucose level prevents or delays the vascular complications of diabetes has been supported so far only by evidence which is largely conjectural.² Such a relationship can be documented only with prospective study of patients randomly assigned to treatment regimens that differ . . . [Full Text PDF of this Article]

Footnotes
Reprint requests to UGDP Coordinating Center, University of Maryland, 610 W Lombard St, Baltimore 21201 (Dr. Knatterud).

For a list of participating investigators and consultants, see page 1409.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?